FDA approves initiation of Phase II clinical trial of MTX652 in Acute Kidney Injury

CAMBRIDGE, England, Dec. 14, 2023. Mission Therapeutics ( " Mission " or the " Company " ), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces that the US Food and Drug Administration (FDA) has approved...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials